Rapid Nexus Receives FDA Clearance for Hemastyl Gel
The FDA 510(k) clearance for its Hemastyl gel device marks the first technology that has treated the tissue surrounding chronic wounds and prevented numerous amputations.
On a significant day in the realm of wound care, Rapid Nexus, a pioneering California-based med-tech company, has announced the receipt of FDA 510(k) clearance for its Hemastyl gel device. This groundbreaking technology is a historic milestone, being the first to directly address the underlying challenges chronic wounds face in the healing process.
Transforming Wound Care Management
For decades, traditional wound care has focused primarily on managing surface-level symptoms. The industry has often centered on merely covering and cleaning wounds, without delving deep into the critical damaged tissue that determines if healing can actually take place. However, Rapid Nexus's newly approved technology is revolutionizing this approach by treating the fundamental tissue environment directly, thereby restoring optimal conditions for wound closure and significantly reducing the risk of amputations.
Insights from Leadership
Dr. Margaret Kalmeta, founder and CEO of Rapid Nexus, expressed her excitement about this FDA clearance, stating, "This FDA clearance validates years of research focused on one of medicine's most persistent challenges—why chronic wounds don't heal. By targeting the periwound tissue—the living edge that determines whether a wound closes or deteriorates—we're giving clinicians a way to help patients who previously had no options."
Understanding Hemastyl Gel Technology
The Hemastyl gel stands as an FDA-cleared topical formulation specifically engineered to promote wound closure by enhancing the local environment required for effective tissue repair. Coupled with this, Rapid Nexus is developing the Periwound NerveStim device, which is nearing the final stages of FDA approval. This innovative device works synergistically with Hemastyl gel to restore tissue function around chronic wounds, addressing the areas predominantly responsible for halted recovery. Together, they represent a transformative approach to wound healing, focusing extensively on the periwound region—an aspect critical to the successful closure of chronic wounds and preventing potential infections or amputations.
Future Prospects and Breakthrough Designation
Exciting developments are on the horizon for Rapid Nexus as the company is finalizing its submission for FDA Breakthrough Device Designation. This designation is anticipated within weeks and comes with the promise of broadening indications for use, alongside accelerated pathways for reimbursement. Such advancements will enhance patient access, particularly for those grappling with chronic wounds and neuropathy.
About Rapid Nexus
Rapid Nexus Nanotech Wound Solutions, Inc. is rooted in California and is committed to developing advanced wound-healing technologies that address core causes of non-healing wounds. With innovations like the Hemastyl gel and the upcoming Periwound NerveStim device, the company is making strides to treat tissue surrounding chronic wounds while aiming to prevent amputations in patients affected by diabetes, trauma, and vascular diseases. In recognition of its potential to advance both civilian and military medicine, Rapid Nexus received a prestigious TechConnect Defense Innovation Award.
Media Contact Information
For any media inquiries, please reach out to:
Sarah Kalmeta
(949) 572-9709
Website: https://rapidnexus.com
Frequently Asked Questions
What is the significance of FDA clearance for Hemastyl?
The FDA clearance marks a pivotal moment in wound care, as Hemastyl is the first treatment to effectively target the core issues associated with chronic wound healing.
How does Hemastyl gel aid in wound healing?
Hemastyl gel improves the local tissue environment necessary for tissue repair, thus facilitating better closure rates and reducing the risk of infections.
Who can benefit from the Hemastyl technology?
Patients suffering from chronic wounds due to diabetes, trauma, or vascular disease are among those who can greatly benefit from Hemastyl technology.
What is the Periwound NerveStim device?
The Periwound NerveStim device, currently in FDA approval stages, complements Hemastyl by restoring tissue function in and around chronic wounds, promoting improved recovery.
What are the next steps for Rapid Nexus after receiving FDA clearance?
Rapid Nexus plans to submit for FDA Breakthrough Device Designation to expand use indications and accelerate patient access to its innovative wound care solutions.
